News
-
16Jun. 2021KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of…
-
2Jun. 2021
-
8Apr. 2021Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy
We are pleased to announce Hadassah important collaboration with MyBiotics for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy
-
10Feb. 2021פיתוח חדש יאפשר לראשונה מעקב בזמן אמת במהלך ניתוחי מוח מורכבים
הטכנולוגיה נולדה בתוכנית ביודיזיין של האוניברסיטה העברית בשיתוף המרכז הרפואי הדסה
-
19Jan. 2021Israel’s BrainWatch Tech is working on prototype of device that will automatically measure and record pupillary reactions to light in patients with severe brain injury
This is the forurh (!) biodesignIsrael company raising seed, coming out of Hadassah and Hebrew University.
-
15Nov. 2020KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
Congratulations to KAHR & Hadasit Bio Holdings (HBL) our portfolio company for announcing First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of…
-
11Oct. 2020Hadassah, Hebrew University and SHL collaboration for developing AI tools in telemedicine
A joint effort is underway to develop AI tools for predicting future life-threatening cardiac events based on full 12 Lead ECG monitoring. Among the team of researchers from the Cardiology…
-
11Mar. 2020ניסוי ניוד תאי הגזע של ביוליין הצליח – והמניה נוסקת
מניית ביוליין עלתה ביום שישי בנאסד”ק ב-33%, לשווי חברה של 39 מיליון דולר • המוצר של ביוליין שהזיכי שלו נרכש מחברת ביוקיין (חברת הפרוטפוליו של הדסית), מיועד לטיפול בסרטן דם
-
26Feb. 2020Cancer treatment co Kahr Medical raises $18m
Jerusalem-based cancer treatment startup Kahr Medical Ltd. has raised $18 million. The round was led by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings (HBL), Pavilion Capital, and Mirae Asset Venture…
-
29Oct. 2019Wohl Institute for Translational Medicine Inaugurated at Hadassah Medical Organization in Jerusalem
Applied Research for Personalized Medicine The Wohl Institute offers state-of-the-art imaging technologies for preclinical research The research at the Wohl Institute will promote the development of dedicated medications and treatments…